Cargando…

E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib

SIMPLE SUMMARY: Inactivating mutations in the CDH1 gene, encoding the cell adhesion protein E-cadherin, cause hereditary diffuse gastric cancer syndrome (HDGC), as well as being a hallmark of sporadic diffuse gastric cancers and lobular breast cancers. We have previously identified AKT3 as a potenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bougen-Zhukov, Nicola, Decourtye-Espiard, Lyvianne, Mitchell, Wilson, Redpath, Kieran, Perkinson, Jacqui, Godwin, Tanis, Black, Michael A., Guilford, Parry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996982/ https://www.ncbi.nlm.nih.gov/pubmed/35406381 http://dx.doi.org/10.3390/cancers14071609

Ejemplares similares

E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors
por: Decourtye-Espiard, Lyvianne, et al.
Publicado: (2021)

Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking
por: Brew, Tom, et al.
Publicado: (2021)

Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2019)

E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function
por: Godwin, Tanis D., et al.
Publicado: (2018)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
por: Karwaciak, Iwona, et al.
Publicado: (2019)

E-cadherin signal sequence disruption: a novel mechanism underlying hereditary cancer
por: Figueiredo, Joana, et al.
Publicado: (2018)

Stimulation of GHRH Neuron Axon Growth by Leptin and Impact of Nutrition during Suckling in Mice
por: Decourtye-Espiard, Lyvianne, et al.
Publicado: (2023)

E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition
por: Chen, Augustine, et al.
Publicado: (2014)

A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells
por: Beetham, Henry, et al.
Publicado: (2019)

Inositol polyphosphate multikinase deficiency leads to aberrant induction of synaptotagmin-2 in the forebrain
por: Park, Jina, et al.
Publicado: (2019)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells
por: Dosch, Austin R., et al.
Publicado: (2019)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Inositol polyphosphate multikinase signaling in the regulation of metabolism
por: Lee, Joo-Young, et al.
Publicado: (2012)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

Impact of insulin on primary arcuate neurons culture is dependent on early-postnatal nutritional status and neuronal subpopulation
por: Decourtye, Lyvianne, et al.
Publicado: (2018)

Sex-Specificity of Mineralocorticoid Target Gene Expression during Renal Development, and Long-Term Consequences
por: Dumeige, Laurence, et al.
Publicado: (2017)

Early spatiotemporal-specific changes in intermediate signals are predictive of cytotoxic sensitivity to TNFα and co-treatments
por: Loo, Lit-Hsin, et al.
Publicado: (2017)

Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012)

Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
por: Miljković, Filip, et al.
Publicado: (2018)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Timing of multikinase inhibitor initiation in differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2017)

Gastrointestinal Tract Homeostasis: The Role of the Inositol Polyphosphate Multikinase
por: Saiardi, Adolfo
Publicado: (2022)

Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1
por: Lippolis, Catia, et al.
Publicado: (2015)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic, Neda, et al.
Publicado: (2014)

Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012)

Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2014)

Clinically relevant drug interactions with multikinase inhibitors: a review
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019)

The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension
por: Uschner, Frank Erhard, et al.
Publicado: (2018)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

The Expanding Significance of Inositol Polyphosphate Multikinase as a Signaling Hub
por: Kim, Eunha, et al.
Publicado: (2017)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
por: Strasma, Anna, et al.
Publicado: (2021)

Inositol Polyphosphate Multikinase Signaling: Multifaceted Functions in Health and Disease
por: Lee, Boah, et al.
Publicado: (2021)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
por: Veeroju, Swathi, et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
por: Zafón, Carles, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gqfg37cedlt0jepul9biq351f2